Abiopharma

🔍 Almstead Neil Gregory (Executive)

Company: PTC THERAPEUTICS, INC. (PTCT)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 39,393 shares of Common Stock at $68.89 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 72,747.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,530 shares of Common Stock at $69.5 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 60,217.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 80 shares of Common Stock at $70.3 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 60,137.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 2,737.00

Footnotes:

• F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
• F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.26 to $69.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
• F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.26 to $70.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.